Acura Pharma (ACUR) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	-8.92M
Depreciation
Non-cash share-based compensation expense	450K
Loss on disposal of property and equipment
Collaboration revenue receivable
Prepaid expenses and other current assets	9K
Accrued expenses	170K
Income taxes payable
Deferred program fee revenue	0
Net cash provided by (used in) operating activities
Cash flows used in investing activities - purchase of property and equipment	-72K
Exercise of stock options
Distribution of restricted stock units	0
Net proceeds from warrant exercise
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options
Net cash provided by (used in) finance activities
Net increase (decrease) in cash and cash equivalents	1.79M
Cash and cash equivalents at beginning of period	2.49M
Cash and cash equivalents at end of period	4.27M
Interest	407K
Income taxes

Entities mentioned with ACUR

View All Entities